RESUMEN
Astragalus, which was first documented in Shennong Bencao Jing, is the dried root of Astragalus membranaceus (Fisch.) Bge. or Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao. The active ingredients astragalus membranaceus saponins (AMS), astragalus polysaccharides (APS) and astragalus flavonoids (AFS) have pharmacological effects such as anti-tumor properties, lowering blood sugar, regulating lipid metabolism, cardiovascular protection, anti-oxidation, bone protection, anti-fibrosis, etc. Fibrosis affects almost all organs, particularly vital organs such as the lungs, liver, heart and kidneys. The primary pathological changes of fibrosis involve abnormal increase of myofibroblasts and excessive deposition of extracellular matrix (ECM) components, which lead to the formation of scar tissue, ultimately resulting in fibrosis and even functional loss or failure of organs, which seriously threatens human health and life. Recent, studies have shown that Astragalus membranaceus has a good therapetuic effect on organ fibrosis. This article reviews the current advances of Astragalus in the prevention and treatment of fibrosis of lungs, liver, heart, kidneys and other important organs.
RESUMEN
Fibrosis can occur in nearly all organs of the body and is an outcome of many chronic diseases. As inflammation leads to necrosis of parenchymal cells， excessive proliferation of fibroblasts and overproduction of extracellular matrix （ECM） occur in tissues and organs， which may cause structural damage and loss of function of organs in the case of continuous progression. Chinese medicine has definite effect on fibrosis and prescriptions with effects of replenishing Qi and activating blood， such as Buyang Huanwutang， are frequently used in clinical settings. Clinical research and experiments show that Buyang Huanwutang can delay the progression of fibrosis in multiple organs such as lung， heart， liver， and kidney by improving organ function， reducing ECM deposition， anti-oxidative stress， anti-inflammatory response， regulating the imbalance of matrix metalloproteinases （MMPs）/tissue inhibitors of metalloproteinases （TIMPs）， and modulating transforming growth factor-β （TGF-β）/Smad pathway. According to traditional Chinese medicine， healthy Qi deficiency is the internal cause of fibrosis， and blood stasis is an important pathological factor in the formation of fibrosis. Moreover， deficiency and stasis exist in the whole process of fibrosis and the changes of microenvironment of fibrotic organs and tissues accord with the pathological manifestations of Qi deficiency and blood stasis. This article reviews the anti-fibrosis mechanism of Buyang Huanwutang in multiple organs， which provides a science-based explanation for the treatment of fibrosis by Buyang Huanwutang and lays a foundation for further clinical research.
RESUMEN
Dahuang Zhechongwan （DHZCW） is a classic prescription from the Jingui Yaolue（《金匮要略》） by ZHANG Zhong-jing，with the effects of tonifying deficiency， relaxing the middle， promoting regeneration， and resolving stasis. It has been widely used in the clinical treatment of various diseases with definite efficacy achieved. The research on multiple organ fibrosis has shown that DHZCW can slow down the development of organ fibrosis in the heart， liver， kidney， lung， etc.， and good results in both clinical practice and experimental research have been obtained. The present study reviewed the previous investigations on the experimental mechanism of DHZCW in the treatment of multiple organ fibrosis and revealed that the pathogenesis was closely related despite different disease sites. From the perspective of traditional Chinese medicine （TCM），these diseases shared a common pathogenesis，which was manifested by deficiency. Long-term diseases led to the formation of "dried blood". From the perspective of modern medicine， the diseases all showed pathological changes in the deposition of extracellular matrix （ECM）， and their occurrence and development were all based on certain effector cells ［such as hepatic stellate cell （HSC） and pancreatic stellate cell （PSC）］， with same cytokines ［such as tumor necrosis factor-α （TNF-α），interleukin-6 （IL-6），IL-1β，and α-smooth muscle actin （α-SMA）］ and some key pathways ［transforming growth factor-β1 （TGF-β1）/Smad， phosphatidylinositol-3-kinase （PI3K）/protein kinase B （Akt）， and lipopolysaccharide （LPS） paracrine and autocrine mechanisms］ involved. As a classic prescription for "deficiency-induced dry blood"， DHZCW was effective in treating fibrosis， which was presumedly related to the inhibition of ECM deposition by intervening in the above-mentioned mechanisms， thereby delaying the disease progression. This study is expected to provide literature support to clarify the scientific connotation of DHZCW in the treatment of multiple organ fibrosis and lay a foundation for further experimental and clinical research.
RESUMEN
Fibrosis is a pathological process characterized by tissue scars and can occur in many organs of the human body. Organ fibrosis is manifested by increased fibrous connective tissue and reduced parenchymal cells in organ tissues, which can lead to destruction of organ structures and reduced function, which seriously endangers human health. Current strategies for treating organ fibrosis include: blocking the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway, anti-inflammatory, regulating the sphingosine kinase 1/sphingosine-1-phosphate (SK1/S1P) signaling pathway, antagonizing vasoactive peptide receptors, enzyme inhibitors, kinase inhibitors, inhibitors of cellular signaling pathway, regulation of metabolic pathways, and mesenchymal stem cell therapy. In the review, the treatment strategies for organ fibrosis and the latest developments in the research of anti-organ fibrosis drugs are summarized to provide a reference for the development of anti-organ fibrosis drugs.
RESUMEN
MicroRNA-21 (miR-21) expression is abnormal in almost all cancer tissues.MiR-21 plays an important role in organ development,immune response and development of cancer,cardiovascular disease,and other physiological or pathological conditions.MiR-21 plays a regulatory function on its targeted molecules in various signal pathways.MiR-21 has been considered as a major investigative object of genetic and pharmacological regulation.Organ fibrosis and malignant tumor have been the main factors limiting human survival life.This paper reviews the role of mir-21 in cardiac fibrosis,renal fibrosis,liver fibrosis and other organs fibrosis.
RESUMEN
Tissue and organ fibrosis is the major cause for disability and death related to a variety of diseases worldwide. As specific therapies to halt, or even to reverse the existing tissue fibrosis are not yet available, it is of great significance to find new anti-fibrosis therapeutic agents. Tissue and organ fibrosis is a nonphysiological scarring process, associated with excessive deposition of extracellular matrix, and leads to impairment of organ function. Fibrotic lesions of all organs show similar histological abnormalities. In recent years, plenty of studies showed that Baicalin and baicalein had anti-fibrosis effects in different tissues or organs. In this paper, the effects and mechanisms of baicalin and baicalein on different organ fibrosis were reviewed. Baicalin and its aglycone baicalein had similarity in structural and pharmacological characteristics, with broad biotransformation effect within the body. The research suggested that baicalin and baicalein can suppress different tissue and organ fibrosis occurrence and development via various mechanisms, including down-regulating expression of promote-fibrosis cytokines, inhibiting pro-fibrogenic signaling pathways, anti-inflammatory and anti-oxidant effects. Though baicalin and baicalein are promising anti-fibrosis agents, there is still a long way to go before being approved as specific anti-fibrotic drugs.
RESUMEN
Abstract Treating different diseases with same method and treating same disease with different methods have profound theoretical origins as an important content of TCM syndrome differentiation and treatment system.This theory is introduced into studies of TCM prevention and treatment of fibrosis and sclerosis of the liver,kidney.lung and other organs to search for effective drugs for common treatment of multiple organ fibrosis.so as to reveal the essenee of fibrosis and sclerosis of organs and open a new way for TCM prevention and treatment of refractory diseases;to provide experimental basis for TCM theory of treating different diseases with same method and treating same disease with different methods,and to provide new thinking and new method for studies of integrated western and Chinese medicine,TCM modernization and standardization.
RESUMEN
Metallothionein is a sulfhydryl-rich,and chelating a large number of metal ions,which is widely found in biological world.It is very highlighted that MT had the same physical and chemical features from different origins.Plenty of research data indicated that MTs contain 20 free sulfhydryl genes,as well as their sulfhydryl clusters,It is a multifunctional protein in health.Many experiments demonstrate that MTs may be a novel target of original new drugs because they play a role in regulating and controlling the organ fibrosis and tumor.